Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects

被引：0
|
作者：
Barbara Finck
Helen Tang
Francesca Civoli
Jennifer Hodge
Hillary O’Kelly
Vladimir Vexler
机构：
[1] Coherus BioSciences,
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Biosimilar; Chemotherapy-induced febrile neutropenia; Granulocyte colony-stimulating factors; Pegfilgrastim; Pegfilgrastim-cbqv; Supportive care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4291 / 4307
页数：16
相关论文
共 50 条
  • [41] A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim
    Waller, Cornelius F.
    Tiessen, Renger G.
    Lawrence, Tracey E.
    Shaw, Andrew
    Liu, Mark Shiyao
    Sharma, Rajiv
    Baczkowski, Mark
    Kothekar, Mudgal A.
    Micales, Catherine E.
    Barve, Abhijit
    Ranganna, Gopinath M.
    Pennella, Eduardo J.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (06) : 1087 - 1095
  • [42] Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects
    Stalker, Dennis
    Reid, Susan
    Ramaiya, Atulkumar
    Wisemandle, Wayne A.
    Martin, Nancy E.
    CLINICAL THERAPEUTICS, 2016, 38 (08) : 1778 - 1788
  • [43] Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial
    Lickliter, Jason
    Kanceva, Radmila
    Vincent, Emmanuelle
    Schueler, Armin
    Harrison-Moench, Eleanor
    Yue, Corinne Seng
    Stahl, Michael
    Ullmann, Martin
    Ghori, Vishal
    Griffin, Paul
    CLINICAL THERAPEUTICS, 2020, 42 (08) : 1508 - +
  • [44] Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Cefiderocol in Chinese Healthy Subjects
    Zhang, Chuhan
    Yu, Shuyan
    Li, Size
    Wu, Xiaojie
    Wei, Qiong
    He, Jinjie
    Cao, Guoying
    Yang, Haijing
    Wang, Jingjing
    Fujitani, Kohei
    Katsube, Takayuki
    Zhang, Jing
    Dou, Honghong
    ADVANCES IN THERAPY, 2025, : 2285 - 2297
  • [45] Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
    Hu, Yingying
    Wei, Qiong
    Bian, Xingchen
    Yang, Xinyi
    Yu, Jicheng
    Wang, Jingjing
    Yang, Haijing
    Cao, Guoying
    Wu, Xiaojie
    Zhang, Jing
    ANTIBIOTICS-BASEL, 2023, 12 (09):
  • [46] Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects
    Brunet, A.
    Hermabessiere, S.
    Benain, X.
    EUROPEAN HEART JOURNAL, 2011, 32 : 618 - 619
  • [47] Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(R) in healthy subjects: A randomized, double-blind trial
    Wynne, Chris
    Schwabe, Christian
    Vincent, Emmanuelle
    Schueler, Armin
    Ryding, Janka
    Ullmann, Martin
    Ghori, Vishal
    Kanceva, Radmila
    Stahl, Michael
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (02):
  • [48] Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects
    Inderjeet Singh
    Anshul Attrey
    Adarsh Garg
    Ronak Patel
    Vinu Jose
    Clinical Drug Investigation, 2021, 41 : 29 - 42
  • [49] Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects
    Singh, Inderjeet
    Attrey, Anshul
    Garg, Adarsh
    Patel, Ronak
    Jose, Vinu
    CLINICAL DRUG INVESTIGATION, 2021, 41 (01) : 29 - 42
  • [50] Pharmacokinetics/pharmacodynamics of Sandoz biosimilar pegfilgrastim compared to both US- and EU-reference pegfilgrastim: A meta-analysis of three clinical studies in healthy subjects
    Nakov, Roumen
    Wang, Jessie
    Bellon, Anne
    Gattu, Sreekanth
    Arani, Ramin
    CANCER RESEARCH, 2020, 80 (04)
12345